HLA-DRA anticorps

N° du produit ABIN6262290

L’anticorps Lapin Polyclonal anti-HLA-DRA a été validé pour WB, IHC, ELISA, IF et ICC. Il convient pour détecter HLA-DRA dans des échantillons de Humain, Rat et Souris.

Aperçu rapide pour HLA-DRA anticorps (ABIN6262290)

Antigène: HLA-DRA (HLA Class II DR alpha (HLA-DRA))

Reactivité: Humain, Rat, Souris

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp HLA-DRA est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (IHC), ELISA, Immunofluorescence (IF), Immunocytochemistry (ICC)

Détail du produit anti-HLA-DRA anticorps

Specificité: HLA-DRA Antibody detects endogenous levels of total HLA-DRA

Réactivité croisée: Humain, Souris, Rat (Rattus)

Purification: The antiserum was purified by peptide affinity chromatography using SulfoLink^TM Coupling Resin (Thermo Fisher Scientific).

Immunogène: A synthesized peptide derived from human HLA-DRA

Isotype: IgG

Information d'application

Indications d'application: WB 1:500-1:2000 IHC 1:50-1:200, IF/ICC 1:100-1:500

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: Rabbit IgG in phosphate buffered saline ,  pH 7.4, 150  mM NaCl, 0.02 % sodium azide and 50 % glycerol.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20 °C.Stable for 12 months from date of receipt

Date de péremption: 12 months

Détails sur HLA-DRA

Antigène: HLA-DRA (HLA Class II DR alpha (HLA-DRA))

Autre désignation: HLA-DRA

Sujet:

Description: Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.

Gene: HLA-DRA

Poids moléculaire: 29kDa

ID gène: 3122

UniProt: P01903

Pathways: TCR Signaling, CXCR4-mediated Signaling Events, Human Leukocyte Antigen (HLA) in Adaptive Immune Response